Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | UCHL5 | Q9Y5K5 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27711089 | 0.85 | ALOX5 (0.53) | CYP2C9HPGDCYP2C19ADRA2CMAOA | |
| SCHEMBL5521073 | 0.80 | ALOX5 (0.49) | CYP2C9HPGDCYP2C19ADRA2CMAOA | |
| SCHEMBL11518982 | 0.79 | ALOX5 (0.51) | CYP2C9HPGDCYP2C19DRD3CYP1A2 | |
| SCHEMBL27484445 | 0.78 | CYP2C9 (0.53) | CYP2C9HPGDCYP2C19ADRA2CMAOA | |
| SCHEMBL1679307 | 0.78 | CYP2C9 (0.53) | CYP2C9HPGDCYP2C19ADRA2CMAOA | |
| SCHEMBL4281496 | 0.77 | ALOX5 (0.54) | CYP2C9HPGDCYP2C19ADRA2CMAOA | |
| SCHEMBL9489532 | 0.76 | ALOX5 (0.49) | CYP2C9HPGDCYP2C19ADRA2CMAOA | |
| SCHEMBL7759137 | 0.76 | CYP2C9 (0.65) | CYP2C9HPGDCYP2C19ADRA2CMAOA | |
| SCHEMBL2068845 | 0.75 | CYP2C9 (0.50) | CYP2C9HPGDCYP2C19ADRA2CMAOA | |
| SCHEMBL2069257 | 0.75 | CYP2C9 (0.50) | CYP2C9HPGDCYP2C19ADRA2CMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| EP-1924546-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | CYP2C9 1627/4885HPGD 1235/4885CYP2C19 896/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | CYP2C9 1824/4885HPGD 1169/4885CYP2C19 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.